Metformin in noninsulin-dependent diabetes mellitus

Pharmacotherapy

Volumn 16, Issue 3 I, 1996, Pages 327-351

  Lee, Audrey Jade ^a,b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOHEXAMIDE; BUFORMIN; CHLORPROPAMIDE; CIMETIDINE; FUROSEMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GUAR GUM; HEMOGLOBIN A1C; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; NIFEDIPINE; ORAL ANTIDIABETIC AGENT; PHENFORMIN; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE;

ANOREXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYANOCOBALAMIN DEFICIENCY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG COST; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN TREATMENT; LACTIC ACIDOSIS; LIPID METABOLISM; META ANALYSIS; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE BLIND PROCEDURE; TASTE DISORDER;

BODY WEIGHT; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 0029895680     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Koda-Kimble MA. Diabetes mellitus. In: Young LY, KodaKimble MA, eds. Applied therapeutics: the clinical use of drugs, 5th ed. Vancouver, WA: Applied Therapeutics, 1992:72-4.
2. Lefebvre PJ, Scheen AJ. Management of non-insulin-dependent diabetes mellitus. Drugs 1992;44:29-38.
3. Lebovitz HE. Oral antidiabetic agents: the emergence of alpha-glucosidase inhibitor. Drugs 1992;44:21-8.
4. Genuth S. Management of the adult onset diabetic with sulfonylurea drug failure. Endocrinol Metab Clin North Am 1992;21:351-70.
5. Bailey CJ, Nattrass M. Treatment-metformin. Baillieres Clin Endocrinol Metab 1988;2:455-76.
6. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992;15:755-72.
7. Bailey CJ. Metformin - an update. Gen Pharmacol 1993;24:1299-1309.
8. Vigneri R, Goldfine I. Role of metformin in treatment of diabetes mellitus. Diabetes Care 1987;10:118-22.
9. Schafer G. Biguanides: a review of history, pharmacodynamicsand therapy. Diabete Metab 1983;9:148-61.
10. Lucis OJ. The status of metformin in Canada. Can Med Assoc J 1983;128:24-6.
11. Bristol-Myers Squibb. Metformin (Glucophage) package insert. Princeton, NJ; 1995.
12. Defronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 1992;15:318-68.
13. Shamoon H. Pathophysiology of diabetes: a review of selected recent developments and their impact on treatment. Drugs 1992:44:1-12.
14. Porte D. Banting lecture 1990: beta-cells in type II diabetes mellitus. Diabetes 1991;40:166-80.
15. Consoli A. Role of liver in pathophysiology of NIDDM. Diabetes Care 1992;15:430-9.
16. Garvey WT. Glucose transport and NIDDM. Diabetes Care 1992;15:396-417.
17. Klip A, Leiter AL. Cellular mechanism of action of metformin. Diabetes Care 1990;13:696-704.
18. Bloomgarden ZT. The American Diabetes Association annual meeting, 1994: treatment issues for NIDDM. Diabetes Care 1994;17:1078-84.
19. Stumvoll M, Nurjahan N, Perriello G, Dailey G, Gerich J. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4.
20. Yu B, Pugazhenthi S, Khandelwal RL. Effects of metformin on glucose and glucagon regulated gluconeogenesis in cultured normal and diabetic hepatocytes Biochem Pharmacol 1994;48:949-54.
21. Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994;43:920-8.
22. Sarabia V, Lam L, Burdett E, Leiter LA, Klip A. Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin. J Clin Invest 1992;90:1386-95.
23. Hundal HS, Ramlal T, Reyes R, Leiter LA, Klip A. Cellular mechanism of metformin action involves glucose transporter from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 1992;131:1165-73.
24. Matthaei S, Reibold JP, Haraann A, et al. In vivo metformin treatment ameliorates insulin resistance: evidence for potentiation of insulin-induced translocation and increased functional activity of glucose transporters in obese (fa/fa) Zucker rat adipocytes. Endocrinology 1993;133:304-11.
25. Kozka IJ, Holman GD. Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. Diabetes 1993;42:1159-65.
26. Galuska D, Nolte LA, Zierath JR, Wallberg-Henriksson H. Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with N1DDM. Diabetologia 1991;34:826-32.
27. Fischer Y, Thomas J, Rosen P, Kammermeier H. Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats. Endocrinology 1995;136:412-20.
28. Rossetti L, Defronzo RA, Gherzi R, et al. Effect of metformin treatment on insulin action in diabetic rats: in vivo and vitro correlations. Metabolism 1990;39:425-35.
29. Johnson AB, Webster JM, Sum C, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993;42:1217-22.
30. Pentikamen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979;16:195-202.
31. Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978;24:683-93.
32. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12:235-46.
33. Marchetti P, Giannarelli R, Di Carlo A, Navalesi R. Pharmacokinetic optimisation of oral hypoglycaemic therapy. Clin Pharmacokinet 1991;21:308-17.
34. Bailey CJ, Mynett KJ, Page T. Importance of the intestine as a site of metformin-stimulated glucose use. Br J Pharmacol 1994;112:671-5.
35. Nathan D. The rationale for glucose control in diabetes mellitus. Endocrinol Metab Clin North Am 1992;21:221-35.
36. Zimmerman BR. Glycaemic control in diabetes mellitus: toward the normal profile? Drugs 1994;47:611-21.
37. Bristol-Myers Squibb. Glucophage formulary kit monograph: Glucophage (metformin hydrochloride tablets). Princeton, NJ; 1995.
38. Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of metformin on postprandial lipemia in patients with fairly poorly controlled NIDDM. Diabetes Care 1994;17:1093-9.
39. Wu M-S, Johnston P, Sheu WH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in patients with NIDDM. Diabetes Care 1990;13:1-8.
40. Defronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-9.
41. Defronzo RA, Goodman A, and the Metformin Investigation Group. Combined metformin/glyburide treatment in patients with NIDDM not optimally responding to maximum dose sulfonylureas; results of a multicenter trial [abstr]. Diabetes 1993;42:146A.
42. Prager R, Schernthaner G. Insulin receptor binding to monocytes, insulin secretion, and glucose tolerance after metformin treatment: results of a double-blind crossover study in type II diabetics. Diabetes 1983;32:1083-6.
43. Fantus IG, Brosseau R. Mechanism of action of metformin insulin receptor and postreceptor effects in vitro and in vivo. J Clin Endocrinol Metab 1986;63:898-905.
44. Lord JM, White SI, Bailey CJ, Watkins TW, Fletcher RF, Taylor KG. Effect of metformin on insulin receptor binding and glycaemic control in type II diabetes. Br Med J 1983;286:830-1.
45. Barzilai N, Simonson D. Mechanism of metformin action NIDDM [abstr]. Diabetes 1988;37:61A.
46. Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 1987;36:632-40.
47. Riccio A, Del Prato S, Vigili de Kreutzenberg S, Tiengo A. Glucose and lipid metabolism in non-insulin-dependent diabetes: effect of metformin. Diabete Metab 1991;17:180-4.
48. Campbell IW, Duncan C, Patton NW, Broadhead T, Tucker GT, Woods HF. The effect of metformin on glycaemic control, intermediary metabolism and blood pressure in non-insulin-dependent diabetes mellitus. Diabet Med 1987;4:337-41.
49. Janka HU. Platelet and endothelial function tests during metformin treatment in diabetes mellitus. Horm Metab Res Suppl 1985;15:120-1.
50. Hother-Nielsen O, Schmitz O, Andersen PH, Beck-Nielsen H, Pedersen O. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol 1989;120:257-65.
51. Pedersen O, Hother-Nielsen O, BakJ, Richelsen B, Beck-Nielsen H, Sorensen N. The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes. Diabet Med 1989;6:249-56.
52. Doman TL, Heller SR, Peck GM, Tattersall RB. Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 1991;14:342-4.
53. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993;16:621-9.
54. Teupe B, Bergis K. Prospective randomized two years of clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete Metab 1991;17:213-17.
55. United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS)13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin inpatients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8.
56. Taylor KG, John WG, Matthews KA, Wright AD. A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-I and B in type 2 (noninsulin-dependent) diabetes. Diabetologia 1982;23:507-10.
57. Clarke BF, Campbell IW. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. Br Med J 1977;2:1576-8.
58. Clarke BF, Duncan LJ. Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics. Lancet 1968;1:123-7.
59. 1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes: a multicenter study. Diabetes 1985;34:793-8.
60. Rains SG, Wilson GA, Richmond W, Elkeles RS. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med 1988;5:653-8.
61. Collier A, Watson HH, Patrick AW, Ludlum CA, Clarke BF. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabete Metab 1989;15:420-5.
62. Josephkutty S, Potter JM. Comparison of tolbutamide and metformin in elderly diabetic patients. Diabet Med 1990;7:510-14.
63. Noury J, Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDDM. Diabete Metab 1991;17:209-12.
64. Boyd K, Rogers C, Boreham C, Andrews WJ, Hadden DR. Insulin, glibenclamide or metformin treatment for noninsulin dependent diabetes: heterogeneous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy. Diabetes Res 1992;19:69-76.
65. Chan JC, Tomlinson B, Critchley JA, Cockram CS, Walden RJ. Metabolic and hemodynamic effects of metformin and glibenclamide in normolensive patients with NIDDM. Diabetes Care 1993;16:1035-8.
66. Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 1994;17:1100-9.
67. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994;11:223-41.
68. Holman RR, Steemson J, Turner RC. Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabet Med 1987;4:457-62.
69. Higginbotham L, Martin FIR. Double-blind trial of metformin in the therapy of non-ketotic diabetics. Med J Aust 1979;2:154-6.
70. Klein W. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy: results of a prospective randomized study in 50 patients. Diabete Metab 1991;17:235-40.
71. Vigneri R, Trischitta V, Italia S, Mazzarino S, Rabuazzo MA, Squatrito S. Treatment of patients with NIDDM with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide. Diabete Metab 1991;17:232-4.
72. Groop L, Widen E. Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy? Diabete Metab 1991;17:218-23.
73. Trischilta V, Italia S, Mazzarino S, et al. Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes Care 1992;15:539-42.
74. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993;44:107-12.
75. Marena S, Tagliaferro V, Montegrosso G, Pagano A, Scaglione L, Pagano G. Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes [abstr]. Diabete Metab 1994;20:15-19.
76. Rains SG, Wilson GA, Richmond W, Elkeles RS. The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy. J R Soc Med 1989;82:93-4.
77. Peacock I, Tattersall RB. The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin? Br Med J 1984;288:1956-9.
78. Dunn FL. Management of hyperlipidemia in diabetes mellitus. Endocrinol Metab Clin North Am 1992;21:395-414.
79. Reaven GM, Johnston P, Hollenbeck CB, et al. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 1992;74:1020-6.
80. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabete Metab 1991;17:224-31.
81. Gustafson A, Bjorntorp P, Fahlen M, Butturini U. Metformin administration in hyperlipidemic States. Acta Med Scand 1971;190:491-4.
82. Schneider J, Erren T, Zofel P, Kaffarnik H. Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus. Atherosclerosis 1990;82:97-103.
83. Arauz-Pacheco C, Raskin P. Management of hypertension in diabetes. Endocrinol Metab Clin North Am 1992;21:371-93.
84. Birkeland KI, Chatzipanagiotou F, Hanssen KF, Vaaler S. Relationship between blood pressure and in vivo action of insulin in type II (non-insulin-dependent) diabetic subjects. Metabolism 1992;41:301-5.
85. Landin-Wilhelmsen K. Metformin and blood pressure. J Clin Pharmacol Ther 1992;17:75-9.
86. Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991;229:181-7.
87. Grant PJ, Stickland MH, Booth NA, Prentice CR. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet Med 1991;8:361-5.
88. Grant PJ. The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects. Diabete Metab 1991;17:168-73.
89. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin and resistance and atherothrombosis. Diabetologica 1991;34:457-62.
90. Montanari G, Bondioli A, Rizzato G, et al. Treatment with low dose metformin in patients with peripheral vascular disease. Pharmacol Res 1992;25:63-73.
91. Sirtori CR. Clinical experience with metformin in patients with peripheral vascular disease. Diabete Metab 1988;14:601-7.
92. Sirtori CR, Franceschini G, Gianfranceschi G, et al. Metformin improves peripheral vascular flow in nonhyperlipidemic patients with arterial disease. J Cardiovasc Pharmacol 1984;6:914-23.
93. Gan SC, Barr J, Arieff AI, Pearl RG. Biguanide-associated lactic acidosis: case report and review of the literature. Arch Intern Med 1992;152:2333-6.
94. Bjorntorp P, Carlstrom S, Fagerberg SE, et al. Influence of phenformin and metformin on exercise induced lactaemia in patients with diabetes mellitus. Diabetologia 1978;15:95-8.
95. Phillips PJ, Scicchitano R, Clarkson AR, Gilmore HR. Metformin associated lactic acidosis. Aust N Z J Med 1978;8:281-4.
96. Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Girard JR. Metformin-induced lactic acidosis in the presence of acute renal failure. Diabetologia 1977;13:211-17.
97. Aguilar C, Reza A, Garcia E, Rull JA. Biguanide related lactic acidosis: incidence and risk factors. Arch Med Res 1992;23:19-24.
98. Campbell IR. Metformin and the sulphonylureas: the comparative risk. Horm Metab Res Suppl 1985;15:105-11.
99. Lalau JD, Vermersch A, Hary L, et al. Type 2 diabetes in the elderly; an assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol 1990;8:329-32.
100. Luft D, Schmulling RM, Eggstein M. Lactic acidosis in biguanide-treated diabetes. Diabetologia 1978;14:75-8.
101. Lalau JD, Westeel PF, Debussche X, et al. Bicarbonate haemodialysis; an adequate treatment for lactic acidosis in diabetics treated by metformin. Intensive Care Med 1987;13:383-7.
102. Lim PS, Huang C, Wei JS. Metformin-induced lactic acidosis: report of a case. J Formos Med Assoc 1992;91:374-6.
103. Lalau JD, Andrejak J, Moriniere P, et al. Hemodialysis in the treatment of lactic acidosis in diabetics by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol 1989;27:285-8.
104. Winter ME. Dialysis of drugs. In: Koda-Kimble MA, Young LY, eds. Basic clinical pharmacokinetics, 3rd ed. Vancouver, WA: Applied Therapeutics, 1994:107-9.
105. Berger W. Incidence of severe side effects during therapy with sulfonylureas and biguanides, Horm Metab Res Suppl 1985;15:111-15.
106. Dandona P, Fonseca V, Mier A, Beckett AG. Diarrhea and metformin in a diabetic clinic. Diabetes Care 1983;6:472-4.
107. Menzies DG, Campbell IW, McBain A, Brown IR. Metformin efficacy and tolerance in obese non-insulin-dependent diabetics: a comparison of two dosage schedules. Curr Med Res Opin 1989;11:273-8.
108. 12 and folic acid serum levels in diabetics under various therapeutic regimens. Diabete Metab 1976;2:187-90.
109. Tomkin GH, Hadden DR, Weaver JA, Montgomery DD. Vitamin BU status of patients on long-term metformin therapy. Br Med J 1971;2:685-7.
110. 12 and intrinsic factor secretion during biguanide therapy. Diabetologia 1983;24:16-18.
111. 12 malabsorption associated with long-term metformin treatment. Br Med J 1980;280:1214-15.
112. Somogyi A, Stockley C, Keal J. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987;23:545-51.
113. Gin H, Orgerie MB, Aubertin J, Keal J, Rolan P, Bochner F. The influence of guar gum on absorption of metformin from the gut in healthy volunteers. Horm Metab Res 1989;21:81-3.
114. Garrett HM, ed. 1995 Red book. Westwood NJ: Medical Economics Data, 1995.